A Phase 1 Single-ascending Dose Study of the Oral Glucocorticoid Receptor Antagonist ORIC-101 in Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 11 Apr 2018
Price : $35 *
At a glance
- Drugs ORIC 101 (Primary)
- Indications Cancer
- Focus Adverse reactions
- Sponsors ORIC Pharmaceuticals
- 03 Apr 2018 Status changed from active, no longer recruiting to completed.
- 12 Dec 2017 Status changed from recruiting to active, no longer recruiting.
- 31 Oct 2017 New trial record